Bruker's (BRKR) Sell (D+) Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a Sell (D+) rating for Bruker (NASDAQ: BRKR) following various adjustments to price targets by other analysts.
• Bruker shares recently traded down 1.8%, with a current price of $39.00 and a consensus rating of "Hold" from analysts.
• The company's quarterly earnings were below expectations, reporting $0.32 EPS against a consensus of $0.33, while revenue decreased compared to the prior year.

Bruker (NASDAQ:BRKR - Get Free Report)'s stock had its "sell (d+)" rating restated by research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

BRKR has been the topic of several other research reports. Bank of America cut their price target on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Stifel Nicolaus set a $40.00 price target on Bruker and gave the stock a "hold" rating in a report on Tuesday, August 5th. Barclays cut their price target on Bruker from $43.00 to $40.00 and set an "overweight" rating on the stock in a report on Thursday, October 2nd. Citigroup cut their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Finally, Wells Fargo & Company cut their price target on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $51.00.

Bruker Trading Down 1.8%

Shares of BRKR stock traded down $0.71 on Friday, hitting $39.00. The stock had a trading volume of 3,353,704 shares, compared to its average volume of 2,818,422. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The firm has a market capitalization of $5.92 billion, a P/E ratio of 75.00, a P/E/G ratio of 5.48 and a beta of 1.20. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64. The company's 50 day moving average price is $33.96 and its 200-day moving average price is $37.02.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. During the same quarter in the prior year, the firm posted $0.52 EPS. Bruker's quarterly revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Analysts anticipate that Bruker will post 2.69 earnings per share for the current year.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the company's stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares of the company's stock, valued at approximately $581,016. This represents a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 27.30% of the company's stock.

Institutional Trading of Bruker

A number of large investors have recently made changes to their positions in the company. Orbis Allan Gray Ltd acquired a new stake in shares of Bruker in the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC boosted its position in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Sculptor Capital LP boosted its position in shares of Bruker by 18.3% in the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company's stock valued at $126,682,000 after purchasing an additional 476,363 shares during the period. Brown Advisory Inc. boosted its position in shares of Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company's stock valued at $113,142,000 after purchasing an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. boosted its position in shares of Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock valued at $67,909,000 after purchasing an additional 796,510 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.